Predicting phthalate bio-burden through medication and dietary supplement exposure
Predicting phthalate bio-burden through medication and dietary supplement exposure
批准号:
9293604
负责人:
Thomas Patrick Ahern
金额:
$8.78万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-04-01 至 2019-03-31
关键词:
AddressAdultAlgorithmsBiologicalBiological AssayBirthCancer ControlCase-Control StudiesCharacteristicsCohort StudiesCollectionComorbidityDataDibutyl PhthalateDiethylhexyl PhthalateDiseaseEndocrineEnrollmentEpidemiologyEquipment and supply inventoriesEstrogen Receptor StatusEstrogen receptor negativeEstrogen receptor positiveEtiologyExcipientsExposure toFemale infertilityFetal DevelopmentGoalsHealthHeterogeneityHormonalIncidenceIndividualInfertilityInvestigationMale InfertilityMalignant NeoplasmsMalignant neoplasm of prostateMalignant neoplasm of testisMeasurementMeasuresMediatingMenopausal StatusMesalamineModelingModernizationNational Health and Nutrition Examination SurveyObesityOutcomeParentsParticipantPatientsPerformancePharmaceutical PreparationsPlayPropranololRanitidineRoleSignal TransductionSpecimenTimeUncertaintyUrineWomen&aposs Healthbasecancer riskcapsulecase controlcohortconsumer productcostdietary supplementsepidemiology studymalignant breast neoplasmphthalatesprediction algorithmpredictive modelingpredictive toolssample collectionstudy populationtooltumorurinary
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT
Phthalates are ubiquitous in modern materials. The U.S. National Health and Nutrition Examination
Survey (NHANES) showed that most U.S. adults have detectable levels of phthalate metabolites in their urine.
This is troubling because phthalates can disrupt normal endocrine signaling, and may therefore drive
hormonally-mediated outcomes including breast cancer, testicular cancer, prostate cancer, cardiometabolic
disorders, male and female infertility, and abnormal fetal development. Despite urgent need for epidemiologic
studies of phthalate health effects, few such studies exist. This lack of evidence is unsurprising because few
epidemiology studies collect urine, which is the only reliable medium for measuring phthalate metabolites.
Several specific drugs (e.g., propranolol, ranitidine, and mesalamine) include products that use phthalates as
excipients to delay or prolong release of active ingredients from capsules. Users of these medications have
phthalate burdens up to 50-fold greater than individuals with only background exposure. Medication users may
therefore help to define highly exposed groups in epidemiologic studies of the health effects of phthalate
exposure.
We will develop predictive models for longitudinal phthalate exposure by capitalizing on existing
medication data and urinary phthalate metabolite measurements from a Women's Health Initiative (WHI)-
nested breast cancer case-control study (500 cases and 1,000 controls). These predictive models will then be
applied to the entire WHI cohort to multiply impute phthalate metabolite levels in all WHI participants
(n>160,000). We will then use the multiply imputed phthalate data to conduct the largest-yet study of breast
cancer risk as a function of longitudinal phthalate exposure. Our models and the multiple imputation framework
may be extended to existing epidemiologic study populations with medication data to permit cost- and time-
efficient investigation into the health effects of phthalate exposure—without having to enroll and follow new
cohorts with appropriate biological specimen collection.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金